Literature DB >> 19809275

Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.

Pedram Gerami1, Amanda Wass, Mariam Mafee, Yuaquin Fang, Melissa P Pulitzer, Klaus J Busam.   

Abstract

Nevoid melanoma may resemble benign compound or intradermal nevi by their silhouette and profile on low power. Higher power usually reveals nuclear atypia, confluence of cells, incomplete maturation and dermal mitotic activity. However, to some extent all of these features maybe seen in benign compound or intradermal nevi and no single criteria can be used to differentiate nevoid melanoma from a benign nevus. The distinction can be particularly problematic in nevi that show mitotic activity and we have noted a recent trend in diagnosis of melanocytic neoplasms with dermal mitosis as nevoid melanoma despite the presence of normal maturation in the dermis and lack of significant nuclear atypia. Therefore in this study we evaluated 10 nevoid melanomas, 4 of which resulted in metastasis and 10 mitotically active nevi with fluorescence in situ hybridization targeting key chromosomal loci previously shown to effectively discriminate been malignant and benign melanocytic neoplasms. All 10 nevoid melanomas showed copy number abnormalities by fluorescence in situ hybridization in either chromosome 6 or 11 while none of the 10 mitotically active nevi did. The results demonstrate that fluorescence in situ hybridization targeting key chromosomal loci on chromosomes 6 and 11 can be effective in discriminating nevoid melanomas from mitotically active nevi. Additionally, our study presents further evidence that dermal mitoses alone without other diagnostic features such as nuclear atypia and lack of maturation does not constitute sufficient evidence alone for a diagnosis of melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809275     DOI: 10.1097/PAS.0b013e3181ba6db6

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

1.  Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions.

Authors:  Klaus J Busam; Heinz Kutzner; Lorenzo Cerroni; Thomas Wiesner
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

Review 2.  [Histological spectrum of malignant melanoma].

Authors:  T Brenn
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

3.  RREB1 transcription factor splice variants in urologic cancer.

Authors:  Matthew D Nitz; Michael A Harding; Steven C Smith; Shibu Thomas; Dan Theodorescu
Journal:  Am J Pathol       Date:  2011-07       Impact factor: 4.307

4.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

5.  Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma.

Authors:  Jeffrey P North; John T Vetto; Rajmohan Murali; Kevin P White; Clifton R White; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

Review 6.  Review of diagnostic, prognostic, and predictive biomarkers in melanoma.

Authors:  Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 7.  Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis.

Authors:  Jayson Miedema; Aleodor A Andea
Journal:  Mod Pathol       Date:  2020-02-17       Impact factor: 7.842

8.  Microrna profiling analysis of differences between the melanoma of young adults and older adults.

Authors:  Drazen M Jukic; Uma N M Rao; Lori Kelly; Jihad S Skaf; Laura M Drogowski; John M Kirkwood; Monica C Panelli
Journal:  J Transl Med       Date:  2010-03-19       Impact factor: 5.531

9.  Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Authors:  Linda Gao; Karin van den Hurk; Peter T M Moerkerk; Jelle J Goeman; Samuel Beck; Nelleke A Gruis; Joost J van den Oord; Véronique J Winnepenninckx; Manon van Engeland; Remco van Doorn
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

Review 10.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.